great
major
commerci
avail
vaccin
tetanu
measl
yellow
fever
vaccin
design
induc
robust
humor
respons
neutral
titer
index
indic
protect
immun
tetanu
measl
yellow
fever
respect
vaccin
recipi
howev
protect
numer
diseas
caus
agent
human
immunodefici
viru
hiv
hepat
c
viru
hcv
plasmodium
parasit
mycobacterium
tuberculosi
lassa
viru
ebolaviru
marburg
viru
induct
humor
cellular
immun
respons
desir
result
consider
effort
put
develop
vector
capabl
gener
cellular
antibodi
ab
respons
target
gene
transgen
adenoviru
ad
deriv
vector
shown
success
elicit
strong
cellular
humor
immun
respons
rodent
nonhuman
primat
nhp
well
human
singl
inject
preclin
studi
among
human
ad
vector
test
deriv
human
adenoviru
serotyp
emerg
gold
standard
immun
due
superior
immunogen
result
earlier
clinic
trial
almost
exclus
perform
use
vector
howev
although
vector
highli
efficaci
preclin
studi
perform
anticip
clinic
trial
due
preexist
immun
particip
natur
exposur
adenovirus
pathogen
caus
common
cold
signific
proport
human
popul
antibodi
virus
due
past
infect
natur
acquir
commun
notabl
childhood
natur
exposur
respons
longlast
immun
preexist
immun
interfer
hadbas
vaccin
phase
trial
individu
preexist
immun
mount
lower
immun
respons
compar
particip
without
preexist
immun
preexist
immun
even
associ
undesir
effect
beyond
neutral
benefit
intend
vaccin
neg
impact
preexist
immun
illustr
infam
step
trial
lower
frequenc
individu
high
ab
titer
develop
cellular
respons
transgen
hiv
gag
pol
nef
furthermor
preexist
immun
associ
increas
hiv
acquisit
vaccin
particip
comparison
placebo
preexist
immun
taken
account
preclin
studi
anim
use
studi
mice
nhp
natur
infect
human
ad
contrast
percentag
african
european
american
popul
neutral
antibodi
nab
document
respect
sinc
realiz
neg
impact
preexist
ad
immun
earli
clinic
trial
better
understand
ultim
circumv
preexist
immun
major
focu
develop
new
ad
base
vaccin
order
reach
goal
preexist
immun
artifici
gener
anim
model
immun
vector
either
lack
foreign
gene
encod
irrelev
one
addit
order
determin
contribut
ad
specif
cell
ab
preexist
immun
cell
serum
ad
immun
anim
transfer
one
review
first
summar
contribut
differ
arm
immun
system
toward
preexist
immun
ad
vector
mechan
evas
main
strategi
develop
circumv
preexist
ad
immun
review
work
preexist
ad
immun
reveal
nab
ad
specif
cell
well
ad
induc
inflammatori
respons
contribut
differ
extent
reduc
ad
vector
efficaci
preimmun
subject
import
nab
reduc
ad
vector
immunogen
extens
demonstr
passiv
transfer
serum
ad
immun
mice
purifi
nab
ad
decreas
ad
transgen
express
well
transgen
specif
cellular
humor
respons
rodent
deplet
ab
three
main
ad
capsid
protein
fiber
penton
hexon
affin
chromatographi
ad
immun
serum
greatli
reduc
inhibitori
effect
sera
vaccin
vector
efficaci
demonstr
almost
complet
restor
transgen
express
level
although
nab
target
main
capsid
protein
detect
vitro
equal
contribut
ad
vector
neutral
vivo
rel
contribut
subset
nab
teas
apart
vaccin
ad
preimmun
anim
capsid
chimer
ad
vector
studi
nab
target
hexon
protein
appear
play
domin
role
vivo
hexon
specif
nab
direct
expos
loop
surfac
viru
particl
expos
loop
also
known
hypervari
region
hvr
replac
entir
hexon
sequenc
simpli
expos
epitop
hexon
hexon
hvr
differ
serotyp
suffici
overcom
preexist
immun
rodent
addit
three
amino
acid
substitut
mutat
one
hvr
abl
greatli
reduc
vitro
neutral
nhp
polyclon
serum
rais
chimpanze
ad
serotyp
deriv
vector
convers
addit
hexon
domain
simian
ad
serotyp
vector
render
chimer
vector
suscept
preexist
immun
illustr
reduc
transgen
express
rodent
contrast
nab
ad
fiber
play
limit
role
vivo
neutral
nab
gener
singl
inject
weakli
neutral
chimer
vector
express
fiber
indic
nab
gener
capsid
protein
convers
nab
gener
singl
inject
readili
neutral
chimer
vector
express
fiber
vivo
preexist
immun
inhibit
express
transgen
chimer
vector
possess
hexon
protein
possess
fiber
protein
passiv
transfer
mous
serum
contain
ab
chimer
express
fiber
impact
cellular
humor
immun
respons
transgen
gener
inject
one
caveat
studi
vivo
nab
target
fiber
less
common
singl
inject
readili
detect
two
immun
adenoviru
howev
anim
studi
preexist
immun
gener
singl
ad
inject
induc
ab
respons
probabl
limit
breath
neutral
titer
compar
humor
respons
gener
individu
repeat
natur
infect
replic
compet
ad
result
studi
may
underestim
role
play
nab
target
ad
fiber
especi
nab
ad
fiber
penton
act
synergist
although
nab
ad
strongli
reduc
ad
vector
immunogen
serotyp
specif
limit
crossneutr
differ
ad
serotyp
fig
lack
crossneutr
due
high
sequenc
heterogen
target
epitop
hexon
hvr
fiber
knob
howev
nonneutr
crossreact
ab
also
gener
especi
repeat
ad
inject
nonneutr
ab
also
reduc
transgen
express
presum
use
variou
fc
receptor
depend
antibodi
depend
cellular
cytotox
complement
mediat
lysi
opsonis
independ
mechan
impact
nonneutr
ab
elegantli
illustr
pichlagollon
colleagu
demonstr
passiv
transfer
ab
abl
bind
neutral
could
reduc
transgen
express
well
immunogen
modifi
vector
inhibitori
effect
crossreact
non
neutral
ab
particular
concern
ab
seem
readili
induc
addit
nab
ad
specif
cell
also
decreas
vector
efficaci
despit
fact
passiv
transfer
either
serum
cell
immun
mice
significantli
decreas
cellular
humor
respons
insert
immun
less
attent
given
role
ad
specif
cell
preexist
ad
vector
immun
although
passiv
transfer
nab
induc
greater
inhibit
induc
immun
respons
inhibit
ad
immun
stimul
level
observ
preimmun
mice
point
contribut
ad
specif
cell
dampen
immunogen
preimmun
subject
deplet
cell
ad
immun
anim
would
provid
accur
evalu
cell
contribut
circul
tissueresid
cell
taken
account
ad
specif
cell
inhibit
vector
efficaci
import
due
crossreact
inde
unlik
nab
ad
specif
cell
abl
recogn
broad
rang
differ
subgroup
fig
sever
group
shown
human
cell
predominantli
recogn
conserv
epitop
adenoviru
hexon
especi
ctermin
region
limit
number
cell
target
fiber
penton
region
addit
wide
crossreact
ad
specif
cell
detect
great
major
test
individu
reactiv
cell
detect
subject
amsterdam
netherland
subject
philadelphia
usa
worth
note
individu
screen
preexist
ad
immun
use
nab
due
wide
distribut
ad
reactiv
cell
preexist
ad
immun
might
widespread
previous
thought
inde
studi
sole
reli
presenc
nab
ad
assess
seropreval
howev
studi
nab
cellular
respons
ad
assess
higher
proport
individu
possess
cell
respons
compar
nab
ad
exampl
studi
calcedo
colleagu
test
individu
neutral
ab
wherea
individu
ad
specif
cell
respons
measur
enzymelink
immunospot
elispot
similarli
higher
proport
individu
ad
specif
cell
respons
compar
neutral
ab
anoth
studi
addit
wide
distribut
crossreact
ad
specif
cell
mainli
effector
memori
cell
could
readili
reactiv
vitro
polyfunct
high
potenc
may
result
frequent
reactiv
infect
differ
ad
serotyp
taken
togeth
due
abil
crossreact
ad
differ
subgroup
widedistribut
human
popul
high
potenc
impact
ad
specif
cell
overlook
develop
futur
ad
vector
addit
ad
specif
b
cell
innat
immun
respons
ad
vector
also
dampen
ad
efficaci
especi
context
preexist
immun
innat
immun
respons
possess
immunolog
memori
except
nk
cell
previous
activ
hapten
cytokin
howev
despit
lack
convent
memori
ad
induc
innat
immun
respons
regul
ad
immunogen
ad
vector
like
viral
vector
activ
innat
immun
respons
upon
inject
variou
pattern
recognit
receptor
prr
includ
retino
acidinduc
gene
rigi
nucleotid
oligomer
domain
nod
like
receptor
nlr
factor
x
tolllik
receptor
tlr
involv
ad
recognit
addit
ad
bind
coxsackieviru
adenoviru
receptor
car
well
integrin
also
involv
process
upon
activ
prr
molecul
trigger
signal
pathway
nfkb
induc
product
numer
proinflammatori
mediat
includ
cytokin
interferon
ifn
b
interleukin
il
b
tumor
necrosi
factor
tnf
chemokin
macrophag
inflammatori
protein
mip
rant
monocyt
chemoattract
protein
mcp
among
proinflammatori
molecul
receptor
well
type
ifn
play
central
role
induc
posit
feedback
loop
turn
produc
addit
proinflammatori
mediat
role
innat
immun
antigen
express
vector
efficaci
ad
immun
reveal
compar
differ
variou
immunogen
first
observ
compar
benchmark
vitro
vivo
vector
lower
immunogen
induc
greater
inflammatori
respons
illustr
higher
level
inflammatori
cytokin
ifna
ifng
chemokin
itac
addit
also
induc
stronger
nk
cell
activ
stronger
ifna
depend
nk
cell
activ
lead
lower
transgen
express
persist
vitro
due
nk
kill
ad
transduc
monocyt
invers
relat
nk
cell
activ
type
ifn
product
transgen
express
confirm
vivo
exampl
rodent
high
type
ifn
level
associ
lower
transgen
express
inde
compar
induc
higher
level
type
ifn
lower
transgen
express
vivo
furthermor
higher
transgen
express
detect
inject
ifnabr
knockout
mice
compar
vector
wild
type
mice
similarli
nk
deplet
prior
immun
increas
transgen
express
level
nk
transplant
opposit
effect
studi
indic
ad
vector
induc
higher
inflamm
nk
activ
lower
transgen
express
persist
note
type
ifn
nk
cell
also
abl
control
express
level
antigen
influenc
cell
respons
mice
model
mous
cytomegaloviru
mcmv
infect
individu
anim
preexist
ad
immun
high
inflammatori
respons
reduc
transgen
express
persist
due
ad
specif
cell
recruit
site
inflamm
subsequ
kill
ad
transduc
antigen
present
cell
apc
fig
worth
note
although
excess
innat
immun
respons
detriment
ad
vector
immunogen
inflammatori
respons
still
requir
trigger
robust
adapt
respons
therefor
good
vaccinederiv
immun
respons
requir
inflammatori
respons
illustr
ifnabr
knockout
mice
studi
depend
immunogen
transgen
knockout
mice
fail
mount
cellular
respons
mount
lower
respons
immun
solut
overcom
preexist
immun
low
seropreval
human
ad
due
import
nab
dampen
ad
vector
efficaci
ad
vector
develop
use
human
ad
low
seropreval
human
popul
among
vector
vector
test
shown
safe
phase
clinic
trial
howev
compar
human
serotyp
vector
base
low
seropreval
includ
shown
lower
immunogen
protect
efficaci
nonhuman
primat
nhp
model
ebola
viru
infect
therefor
question
clinic
util
addit
lower
immunogen
protect
efficaci
vector
base
low
seropreval
serotyp
probabl
also
suffer
preexist
ad
specif
cell
although
specif
neutral
ab
crossreact
specif
cell
common
human
popul
abl
crossreact
furthermor
crossreact
cell
detect
individu
lack
nab
anim
deriv
adenovirus
due
lower
immunogen
low
seropreval
deriv
vector
attent
shift
toward
develop
vector
base
anim
ad
among
chimpanze
deriv
ad
vector
chad
studi
nab
simian
ad
vector
rel
rare
exampl
nab
detect
less
american
european
chines
african
popul
frequenc
nab
similar
popul
except
africa
peak
furthermor
unlik
rare
human
ad
serotyp
chad
demonstr
great
efficaci
preclin
studi
includ
mous
model
ebov
infect
nhp
model
rabi
combin
modifi
vaccinia
ankara
mva
boost
malaria
mous
model
rodent
model
rift
valley
fever
rvf
addit
phase
clinic
trial
malaria
hcv
respect
found
safe
abl
gener
robust
broad
polyfunct
cell
respons
transgen
although
chad
vector
appear
promis
crossreact
preexist
cellular
immun
ad
overlook
inde
vitro
specif
cell
crossreact
chad
vector
similarli
ad
specif
cell
human
cohort
recogn
well
simian
deriv
ad
similar
extent
could
expect
due
close
phylogenet
proxim
human
chimpanze
ad
specif
highli
conserv
hexon
ctermin
sequenc
recogn
ad
crossreact
cell
inhibitori
role
ad
specif
cell
chad
vector
confirm
anim
model
rare
occas
mous
model
malaria
infect
preexist
immun
reduc
protect
mediat
chad
immun
howev
anim
model
although
chad
induc
protect
impact
preexist
immun
chad
induc
immun
respons
tend
lower
presenc
preexist
immun
worth
note
anim
model
mention
might
underestim
import
cellular
immun
preclin
studi
preexist
immun
usual
gener
singl
inject
replic
defici
ad
vector
artifici
preexist
immun
may
recapitul
potent
ad
specif
cell
respons
observ
human
follow
repeat
exposur
replic
compet
ad
initi
product
infect
inde
primat
multipl
exposur
replic
compet
ad
time
give
rise
polyfunct
highli
potent
cell
addit
chimpanze
ad
vector
bovin
porcin
ovin
canin
fowl
deriv
ad
vector
current
preclin
stage
develop
nab
vector
includ
porcin
ad
serotyp
bovin
ad
serotyp
ovin
ad
serotyp
detect
human
popul
similar
simian
ad
vector
crossnab
gener
mice
immun
furthermor
littl
cell
crossreact
detect
immun
mice
final
immun
either
vaccin
protect
preimmun
mice
influenza
viru
challeng
humor
cellular
immun
respons
impact
preexist
immun
similarli
transgen
express
cellular
respons
affect
preimmun
mice
oadv
inject
respect
howev
although
promis
result
obtain
rodent
use
nonprim
adderiv
vector
includ
bad
pad
oad
use
need
ultim
confirm
human
whether
ad
crossreact
cell
react
bad
pad
still
need
assess
cellular
immun
respons
heavili
influenc
mhc
allel
differ
mice
human
vari
immun
rout
addit
use
altern
ad
serotyp
preexist
immun
overcom
vari
rout
immun
inde
mice
preexist
immun
gener
intranas
intramuscular
immun
experi
reduc
humor
respons
upon
subsequ
oral
immun
similarli
nhp
model
ebola
viru
mediat
protect
intranasalintratrach
immun
impact
preexist
immun
gener
intramuscular
im
inject
irrelev
vector
lack
impact
despit
preexist
immun
may
due
evas
tissu
resid
ad
specif
cell
tissu
resid
memori
cell
rm
memori
cell
unlik
effector
memori
em
cell
circul
blood
extralymphoid
organ
circul
remain
confin
tissu
origin
infect
occur
review
see
ref
rm
shown
induc
better
protect
compar
em
use
parabiot
mice
skin
resid
cell
shown
confer
better
protect
vaccinia
viru
skin
infect
compar
circul
memori
cell
similarli
rm
induc
greater
viral
load
reduct
skin
vagin
infect
herp
simplex
viru
hsv
compar
em
addit
rm
still
detect
tissu
effector
memori
cell
longer
visibl
circul
tissu
specif
rm
mainli
determin
prime
tissu
deriv
migratori
dendrit
cell
dc
migratori
dc
differ
tissu
induc
rm
differ
home
molecul
therefor
differ
tissu
specif
variou
immun
rout
result
antigen
ag
present
distinct
tissu
deriv
migratori
dc
therefor
gener
rm
differ
tissu
specif
fig
richardson
colleagu
studi
im
inject
probabl
gener
rm
lung
subsequ
airway
immun
intranas
intratrach
would
affect
previous
gener
ad
specif
em
circul
rm
would
absent
lung
abil
detect
ad
specif
cell
human
colon
biopsi
well
nhp
gut
ileum
colon
rectum
support
exist
ad
specif
rm
howev
limit
use
differ
immun
rout
circumv
ad
preexist
immun
limit
rout
immun
includ
intraderm
oral
intranasalintratrach
im
sublingu
intraven
iv
latter
may
best
rout
ad
vector
immun
one
fatal
report
gene
therapi
clinic
trial
furthermor
rout
natur
ad
infect
consid
order
determin
put
ad
specif
rm
locat
human
natur
ad
infect
mainli
target
respiratori
tract
lower
extend
eye
gut
urinari
tract
infect
individu
therefor
ad
specif
rm
may
present
lung
gastrointestin
tract
ad
immun
individu
may
affect
intranasalintratrach
oral
immun
respect
need
evalu
experiment
futur
infect
vaccin
ab
readili
migrat
throughout
bodi
demonstr
system
administr
monoclon
ab
treat
variou
solid
cancer
locat
differ
tissu
breast
colorect
gastric
kidney
howev
ab
persist
organ
interestingli
nab
could
detect
airway
cohort
volunt
natur
expos
includ
possess
high
level
circul
specif
nab
blood
like
due
rapid
turnov
immun
cell
iga
type
antibodi
airway
make
admedi
vaccin
site
promis
primeboost
regimen
may
also
help
overcom
preexist
ad
immun
primeboost
regimen
bypass
preexist
ad
immun
per
se
immun
respons
induc
primeboost
regimen
still
decreas
preexist
immun
howev
suffici
magnitud
still
confer
protect
inde
robust
immun
respons
obtain
heterolog
primeboost
regimen
compar
singl
vaccin
homolog
primeboost
immun
rule
also
hold
true
heterolog
ad
primeboost
regimen
use
primeboost
regimen
overcom
preexist
ad
immun
demonstr
decad
ago
use
sever
dna
prime
follow
singl
ad
boost
yang
colleagu
demonstr
cellular
respons
gener
dna
prime
boost
affect
preexist
immun
addit
although
gener
humor
respons
significantli
reduc
preexist
immun
antibodi
titer
obtain
similar
gener
mice
immun
homolog
primeboost
abil
dna
prime
circumv
preexist
immun
suggest
clinic
trial
test
individu
preexist
immun
affect
cell
respons
induc
dna
prime
boost
regimen
preexist
immun
decreas
cellular
respons
gener
singl
inject
addit
dnahad
heterolog
primeboost
regimen
involv
ad
differ
serotyp
may
also
prove
protect
immun
subject
preclin
studi
involv
primeboost
immun
shown
encourag
sign
inde
although
compar
anim
immun
respons
gener
primeboost
immun
decreas
preimmun
nhp
stronger
humor
respons
obtain
compar
homolog
primeboost
final
great
interest
determin
whether
primeboost
regimen
includ
ad
vector
combin
vaccin
platform
modifi
vaccinia
viru
ankara
mva
also
abl
provid
protect
despit
preexist
immun
inde
preclin
studi
regimen
involv
mva
ad
encod
plasmodium
berghei
cs
protein
sever
acut
respiratori
syndrom
sar
protein
abl
induc
robust
cell
ab
respons
higher
magnitud
addna
regimen
express
insert
primeboost
even
test
variou
stage
clinic
trial
malaria
hiv
hcv
result
trial
crucial
term
determin
abil
chadmva
primeboost
regimen
overcom
preexist
immun
worth
note
primeboost
immun
also
use
overcom
preexist
mva
immun
one
attract
featur
develop
primeboost
regimen
circumv
preexist
immun
requir
develop
addit
ad
vector
exist
ad
vector
especi
robust
immunogen
use
howev
determin
numer
vaccin
platform
avail
includ
dna
vsv
aav
mva
best
suit
prime
boost
ad
vector
crucial
addit
primeboost
regimen
time
consum
thu
preclud
rapid
induct
protect
immun
desir
emerg
vaccin
situat
exampl
pathogen
emerg
reemerg
sporad
unpredict
locat
tremend
effort
made
circumv
preexist
ad
immun
human
popul
import
focu
figur
model
tissu
resid
cell
induct
variou
vaccin
rout
major
vector
insert
specif
tissu
resid
cell
resid
close
site
immun
tissu
antigen
first
encount
resid
cell
migrat
away
inject
site
remain
within
tissu
depend
immun
rout
gener
tissu
resid
cell
resid
differ
tissu
note
circul
cell
depict
develop
new
anim
base
ad
vector
especi
ad
vector
simian
origin
vector
preclin
phase
develop
includ
reach
clinic
trial
select
altern
ad
serotyp
mainli
driven
absenc
neutral
ab
serotyp
human
popul
howev
impact
ad
specif
cell
efficaci
vector
mainli
overlook
part
due
complex
natur
cell
assay
design
detect
antiad
cell
respons
compar
nab
assay
cell
assay
requir
complex
stimulatori
condit
andor
multiparametr
flow
cytometri
studi
ad
specif
cell
respons
complic
presenc
rm
circul
blood
isol
cell
usual
requir
mechan
andor
enzymat
disrupt
tissu
interest
isol
procedur
affect
cell
viabil
function
complic
analysi
rm
cell
addit
obviou
ethic
reason
isol
rm
cell
restrict
anim
model
tissu
except
skin
gut
although
harder
obtain
inform
regard
ad
specif
circul
tissu
resid
cell
necessari
full
understand
preexist
immun
ad
vector
select
appropri
ad
vector
clinic
use
therefor
abil
ad
specif
cell
target
popul
crossreact
ad
vector
develop
chimpanze
porcin
bovin
ovin
systemat
investig
preclin
studi
altern
immun
rout
bypass
preexist
ad
immun
immun
airway
hold
promis
may
turn
deliveri
method
choic
induc
potent
long
last
protect
immun
respons
ad
vector
airway
may
viabl
solut
bypass
preexist
immun
sever
remain
question
need
address
despit
rel
rapid
turnov
resid
immun
cell
iga
lung
effect
immun
stimul
follow
natur
ad
exposur
vaccin
critic
determin
whether
ad
vector
readminist
airway
frequenc
accord
regimen
singl
dose
vs
primeboost
knowledg
ultim
inform
number
independ
vaccin
one
antigen
ad
backbon
could
use
ultim
determin
clinic
studi
addit
heterolog
primeboost
regimen
involv
ad
vector
optim
immun
respons
gener
primeboost
regimen
may
suffici
induc
full
protect
despit
preexist
ad
immun
develop
primeboost
regimen
use
ad
vector
limit
nab
crossreact
cell
target
popul
increas
chanc
success
howev
optim
primeboost
regimen
labor
intens
due
increas
number
avail
vaccin
platform
use
data
regard
abil
primeboost
regimen
overcom
preexist
immun
certainli
gener
clinic
trial
involv
chadmva
primeboost
care
analysi
trial
provid
crucial
protect
inform
presenc
absenc
preexist
ad
immun
addit
futur
clinic
trial
involv
ad
vector
also
determin
whether
adbas
vaccin
regimen
impact
hiv
acquisit
although
immun
increas
hiv
acquisit
particip
preexist
immun
step
trial
whether
trend
hold
true
ad
vector
express
differ
insert
need
systemat
evalu
upcom
clinic
trial
perform
popul
high
risk
hiv
infect
address
critic
issu
potenti
conflict
interest
disclos
